Chengdu Ucello Biotechnology Co., Ltd.

This early-phase study tests whether a personalized CAR T-cell therapy can safely shrink advanced solid tumors that carry the CLDN18.2 protein. About 18 adults whose cancer has not responded to standard treatments will receive their own modified immune cells. The main goals are t…

This early-phase trial tests a new treatment called CD19/BCMA CAR-T cell therapy for adults with refractory systemic lupus erythematosus (SLE) who have not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and attack lupus-causing…